Kelly CRISPR & Gene Editing Technology ETF (XDNA) Stock Analysis

Kelly CRISPR & Gene Editing Technology ETF (XDNA) Financial Services Profile

Kelly CRISPR & Gene Editing Technology ETF (XDNA) offers investors exposure to the rapidly evolving DNA modification technology sector through a passive management strategy. The fund tracks a rules-based index of companies engaged in the creation, development, and distribution of DNA modification technologies, focusing on total return performance.

What Is the Investment Thesis for XDNA?

Kelly CRISPR & Gene Editing Technology ETF (XDNA) presents an investment opportunity centered on the growth of the DNA modification technology sector. The fund's passive management approach seeks to replicate the returns of its underlying index, providing exposure to companies involved in CRISPR and gene editing. Key value drivers include the increasing adoption of gene editing technologies in healthcare and agriculture. Growth catalysts include ongoing advancements in CRISPR technology and regulatory approvals for gene therapies. Potential risks involve regulatory hurdles, ethical concerns surrounding gene editing, and competition from other biotechnology companies. Investors may want to evaluate the non-diversified nature of the fund, which may lead to increased volatility. The absence of a dividend yield means returns are solely dependent on capital appreciation.

Based on FMP financials and quantitative analysis

XDNA Key Highlights

The fund invests at least 80% of its net assets in DNA Modification Technology Companies, ensuring focused exposure.

• XDNA is a non-diversified fund, which may lead to higher volatility compared to diversified ETFs.
• The fund employs a passive management approach, tracking a rules-based index for transparent investment strategy.
• XDNA offers targeted exposure to companies involved in the creation, development, and distribution of DNA modification technologies.
• The ETF does not offer a dividend yield, focusing solely on capital appreciation.

Who Are XDNA's Competitors?

XDNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XDNA's Key Strengths?

Targeted exposure to the high-growth DNA modification technology sector.

• Passive management approach provides cost-efficiency.
• Transparent investment strategy through a rules-based index.
• Potential for high returns driven by advancements in gene editing.

What Are XDNA's Weaknesses?

Non-diversified nature may lead to higher volatility.

• Lack of dividend yield may not appeal to income-seeking investors.
• Vulnerability to regulatory changes and ethical concerns surrounding gene editing.
• Reliance on the performance of a specific sector.

What Could Drive XDNA Stock Higher?

Regulatory approvals for new gene therapies could drive significant growth in the sector.

• Advancements in CRISPR technology may lead to new applications and market expansion.
• Increasing adoption of gene editing in agriculture could boost demand for related products and services.

What Are the Key Risks for XDNA?

Regulatory hurdles and ethical concerns surrounding gene editing could delay or limit market growth.

• Competition from other biotechnology companies and ETFs could impact XDNA's performance.
• The non-diversified nature of the fund may lead to higher volatility compared to diversified ETFs.

What Are the Growth Opportunities for XDNA?

• Increasing Adoption of Gene Editing in Healthcare: The market for gene editing technologies in healthcare is projected to grow significantly as more gene therapies receive regulatory approval and demonstrate clinical efficacy. XDNA is positioned to benefit from this trend by investing in companies developing and commercializing gene editing tools and therapies.
• Expansion into Agricultural Applications: Gene editing technologies are being increasingly used in agriculture to improve crop yields, enhance nutritional content, and develop disease-resistant plants. XDNA's portfolio companies may capitalize on this trend by developing and commercializing gene-edited seeds and agricultural products. The agricultural gene editing market presents a substantial growth opportunity, with potential to address global food security challenges.
• Advancements in CRISPR Technology: Ongoing research and development efforts are focused on improving the precision, efficiency, and safety of CRISPR-based gene editing tools. These advancements could lead to new applications and expand the market for gene editing technologies. XDNA's holdings in companies involved in CRISPR research and development position it to benefit from these technological breakthroughs.
• Strategic Partnerships and Collaborations: Companies in the DNA modification technology sector are increasingly forming strategic partnerships and collaborations to accelerate research, development, and commercialization efforts. These collaborations can provide access to new technologies, expand market reach, and share development costs. XDNA's portfolio companies may benefit from these partnerships, driving growth and innovation.
• Regulatory Approvals for Gene Therapies: Regulatory approvals for gene therapies are a key catalyst for the growth of the DNA modification technology sector. As more gene therapies receive approval from regulatory agencies like the FDA, the market for these therapies will expand, driving revenue growth for companies in the sector. XDNA's investments in companies developing gene therapies position it to benefit from these regulatory milestones.

What Threats Does XDNA Face?

• Competition from other biotechnology and genomics ETFs.
• Potential setbacks in gene therapy development.
• Negative public perception of gene editing technologies.
• Economic downturn impacting the biotechnology sector.

What Are XDNA's Competitive Advantages?

• Specialized Focus: XDNA offers a focused investment strategy targeting the DNA modification technology sector, providing a unique offering compared to broader biotechnology ETFs.
• Passive Management: The fund's passive management approach provides a cost-effective way to access the gene editing market.
• Rules-Based Index: The fund tracks a rules-based index, offering transparency in its investment selection process.

What Does XDNA Do?

Kelly CRISPR & Gene Editing Technology ETF (XDNA) is designed to provide investors with targeted exposure to companies at the forefront of DNA modification technologies. The fund operates under a passive management investment approach, aiming to replicate the total return performance of a specific rules-based index. This index comprises stocks and depositary receipts of companies actively involved in various aspects of the DNA modification technology business, including creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing, or franchising. XDNA invests a minimum of 80% of its net assets in DNA Modification Technology Companies, ensuring a focused approach within this specialized sector. As a non-diversified fund, XDNA concentrates its investments in a smaller number of holdings compared to diversified funds, which may result in higher volatility. The ETF's investment strategy is geared towards capturing the growth potential of the DNA modification technology industry, making it a potentially noteworthy option for investors seeking exposure to this innovative field. The fund's passive management style aims to mirror the index's performance, offering a transparent and cost-effective way to access this specific market segment.

What Products and Services Does XDNA Offer?

• Invests in companies engaged in DNA modification technologies.
• Tracks the total return performance of a rules-based index.
• Focuses on companies involved in the creation, development, and distribution of DNA modification technologies.
• Employs a passive management investment approach.
• Invests at least 80% of its net assets in DNA Modification Technology Companies.
• Offers investors targeted exposure to the gene editing sector.

How Does XDNA Make Money?

• The fund generates revenue through management fees charged to investors.
• It aims to replicate the performance of its underlying index, providing a return linked to the DNA modification technology sector.
• The fund's value is derived from the performance of its holdings in DNA modification technology companies.

What Industry Does XDNA Operate In?

Kelly CRISPR & Gene Editing Technology ETF (XDNA) operates within the asset management industry, specifically targeting the DNA modification technology sector. This sector is experiencing growth driven by advancements in gene editing technologies and their applications in healthcare, agriculture, and other fields. The competitive landscape includes other ETFs and investment funds focused on biotechnology and genomics, such as KGHG, KMET, MCRO, RIGZ, and SCIJ. XDNA's non-diversified approach differentiates it, offering concentrated exposure to DNA modification companies, but also potentially increasing risk.

Who Are XDNA's Key Customers?

• Institutional investors seeking exposure to the gene editing sector.
• Retail investors interested in thematic investing in biotechnology.
• Financial advisors looking for specialized investment products for their clients.

XDNA Valuation & Market Position

With a $2.58M market cap, Kelly CRISPR & Gene Editing Technology ETF sits in the micro-cap segment of the market.

Return on equity for Kelly CRISPR & Gene Editing Technology ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. XDNA trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

XDNA Financials

XDNA Latest News

No recent news available for XDNA.

What Investors Ask About Kelly CRISPR & Gene Editing Technology ETF (XDNA) — Financial Services

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources